Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Size & Share, by Therapy Type (Chemotherapy, Immunotherapy, Radiotherapy, Hormonal Therapy); Application (General Medical & Surgical Hospitals, Specialty Hospitals, Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Request Free Sample Copy

Report ID: 2884
Published Date: Mar 13, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Landscape

Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Astellas Pharma Inc.
Clovis Oncology, Inc.
Johnson & Johnson Health Care Systems Inc.
Bayer AG
Orion Corporation
Merck & Co., Inc.
Novartis AG
AstraZeneca PLC

Browse Key Market Insights with Data Illustration:

Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Report 2035

In the News

Astellas Pharma Inc. to conduct clinical trials to develop cell therapy. The development pipeline of the company includes high unmet medical needs such as autoimmune & cardiovascular diseases and cancer. The cell therapy research of the company is based on pluripotent stem cells (PSC)
Clovis Oncology, Inc. to present data from Phase 3 trial, “TRITON3: A Phase 3 Study of Rucaparib vs. Physician’s Choice of Therapy inmCRPC Associated with Homologous Recombination Deficiency (HRD)”. The trial is associated with men with metastatic castration-resistant prostate cancer.

Frequently Asked Questions (FAQ)

Growing prevalence of prostate cancer and growth in the investment and R&D activities in oncology are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2023-2035.

Expensive nmCRPC treatment therapies and lack of awareness about the disease in lower economic regions are estimated to be the growth-hindering factors for market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Astellas Pharma Inc., Clovis Oncology, Inc., Johnson & Johnson Health Care Systems Inc., Bayer AG, Orion Corporation, Merck & Co., Inc., Novartis AG, AstraZeneca PLC, and others.

The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by therapy type, application, and by region.

The hormonal therapy segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Companies Dominating the Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the non-metastatic castration resistant prostate cancer treatment market?

What would be the CAGR of non-metastatic castration resistant prostate cancer treatment market over the forecast period?

What are the challenges affecting the non-metastatic castration resistant prostate cancer treatment market growth?

Which region will provide more business opportunities for growth of non-metastatic castration resistant prostate cancer treatment market in future?

Who are the major players dominating the non-metastatic castration resistant prostate cancer treatment market?

How are the company profiles selected?

What are the segments in the non-metastatic castration resistant prostate cancer treatment market?

Which segment captures the largest market size in the therapy type segment in the non-metastatic castration resistant prostate cancer (nmCRPC) treatment market?